Designing an Ivermectin-Based Patentable Analogy for Cancer Therapy. Strategies in Drug Development and Targeted Delivery
Abstract: Cancer globally continues to be one of the leading causes of death and ranks as the second leading cause of mortality in the United States. Nevertheless, early detection and innovative treatment options can significantly enhance cancer care, improving patients' quality of life and longevity. Current cancer therapies, which include surgery, radiation, chemotherapy, and immunotherapy, often encounter challenges related to selectivity for specific tumors and ineffective drug delivery mechanisms. These hurdles can result in low therapeutic efficacy and increased costs for patients. The development of innovative cancer therapies is increasingly focused on targeted, cost-effective solutions that address the limitations of traditional treatments. This study explores the potential of designing a patentable analog of Ivermectin, a known antiparasitic agent, for application in oncology. Drawing from structural pharmacology, the research emphasizes techniques such as pharmacophore modeling, scaffold design, hybridization with benzimidazole derivatives, and biosostric replacements to enhance drug efficacy and selectivity. It also outlines delivery mechanisms involving nanocarriers and prodrugs for improved therapeutic outcomes. By evaluating Ivermectin structural attributes and precedents in hormone analogs, the paper advocates pharmaceutical innovation through analog development.
Keywords: Ivermectin analog, cancer therapy, nanocarriers, drug repurposing, targeted delivery
How to Cite?: Sahr Andipore Suluku, "Designing an Ivermectin-Based Patentable Analogy for Cancer Therapy. Strategies in Drug Development and Targeted Delivery", Volume 14 Issue 12, December 2025, International Journal of Science and Research (IJSR), Pages: 1547-1555, https://www.ijsr.net/getabstract.php?paperid=SR251209093958, DOI: https://dx.doi.org/10.21275/SR251209093958